In a landmark development, ACTCELLBIO, a pioneering developer and distributor of blood cell activation devices, has signed a strategic Memorandum of Understanding (MoU) with Taepyeong Seoul Hospital, India’s Rejua Energy Center LLP, and Evergreen Ventures. The collaboration aims to introduce cutting-edge Korean medical devices and advanced therapeutic technologies to the Indian market, signaling a significant step in cross-border healthcare innovation.

Groundbreaking Collaboration

This agreement marks a pivotal milestone, creating a gateway for the export of advanced Korean medical technology to emerging markets like India. ACTCELLBIO's blood cell activation devices, known for revolutionizing platelet-rich plasma (PRP) therapy, have garnered substantial attention from leading medical bodies, including the Korean Association of Stem Cell Therapy and the Korean Society for Anti-Aging Medicine.

Rejua Energy Center LLP, an esteemed Ayurvedic medical institution with over 40 clinics in Mumbai, specializes in treatments such as acupuncture, cupping, hydrogen therapy, and prana therapy—rooted in India’s 3,000-year-old traditional medicine. During their recent visit to Korea, Rejua signed an MoU with Taepyeong Seoul Hospital to foster medical technology collaboration and secured a supply agreement with ACTCELLBIO for blood cell activation devices and consumables.

Dr. Lee Sang-gu, Director and CEO of Taepyeong Seoul Hospital, personally guided the Rejua delegation during their visit, showcasing advanced therapies like oxygen therapy, hydrogen therapy, and EMS (electro-muscular stimulation) systems. The delegation expressed keen interest in exploring synergies between Ayurvedic concepts and Korean medical advancements, proposing deeper academic exchanges between the two institutions.

Support for Expanding Korean Expertise

Evergreen Ventures, led by CEO Gaurav Kumar, has committed comprehensive support for the initiative, including education, training, regulatory approvals, medical equipment procurement, and seamless customs clearance. This support ensures the smooth export of Korean medical technologies to India without additional implementation agreements.

“India, with its 1.4 billion population, represents an enormous opportunity for Korean medical companies. What was once considered a distant possibility is now becoming a reality,” said Moon Sang-ho, CEO of ACTCELLBIO. The company is also eyeing further expansion into the Middle East and Southeast Asia, building on the momentum generated by its success in India.

Forging Global Healthcare Alliances

The collaboration underscores the potential for synergy between Ayurvedic and Korean traditional medicine, highlighted by the recent success of Dongbang Medical's acupuncture and cupping device exports. These partnerships are expected to play a significant role in globalizing Korean Oriental medicine while enhancing the reach of Ayurvedic practices.

This historic initiative not only paves the way for cross-border medical innovation but also fosters cultural exchange, signaling a promising future for healthcare collaboration on a global scale.